MX2010008940A - Sistemas de administracion de drogas que contienen estradiol. - Google Patents

Sistemas de administracion de drogas que contienen estradiol.

Info

Publication number
MX2010008940A
MX2010008940A MX2010008940A MX2010008940A MX2010008940A MX 2010008940 A MX2010008940 A MX 2010008940A MX 2010008940 A MX2010008940 A MX 2010008940A MX 2010008940 A MX2010008940 A MX 2010008940A MX 2010008940 A MX2010008940 A MX 2010008940A
Authority
MX
Mexico
Prior art keywords
drug delivery
estradiol
delivery system
containing drug
wafers
Prior art date
Application number
MX2010008940A
Other languages
English (en)
Inventor
Adrian Funke
Christian Zurth
Konstanze Diefenbach
Sascha General
Ildiko Terebesi
Sofia Alincic-Kunz
Matthias Schaefers
Thomas Holler
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010008940(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MX2010008940A publication Critical patent/MX2010008940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Abstract

La presente invención se refiere a sistemas de administración de drogas en la forma de películas delgadas solubles en agua (obleas), que contienen estradiol, o derivados del mismo, en cantidades bajas. Las obleas de la presente invención son adecuadas para tratar, aliviar o prevenir una condición física en un mamífero hembra causada por niveles endógenos de estrógeno insuficientes.
MX2010008940A 2008-02-13 2009-02-05 Sistemas de administracion de drogas que contienen estradiol. MX2010008940A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2830208P 2008-02-13 2008-02-13
EP08002633 2008-02-13
PCT/EP2009/051303 WO2009101021A2 (en) 2008-02-13 2009-02-05 Estradiol-containing drug delivery system

Publications (1)

Publication Number Publication Date
MX2010008940A true MX2010008940A (es) 2010-10-05

Family

ID=39365963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008940A MX2010008940A (es) 2008-02-13 2009-02-05 Sistemas de administracion de drogas que contienen estradiol.

Country Status (27)

Country Link
US (1) US20110097405A1 (es)
EP (1) EP2249803A2 (es)
JP (1) JP2011511823A (es)
KR (1) KR20100125309A (es)
CN (1) CN101945646A (es)
AR (1) AR070375A1 (es)
AU (1) AU2009214193A1 (es)
BR (1) BRPI0908477A2 (es)
CA (1) CA2714340A1 (es)
CL (1) CL2009000326A1 (es)
CO (1) CO6290633A2 (es)
CR (1) CR11632A (es)
DO (1) DOP2010000252A (es)
EA (1) EA201001245A1 (es)
EC (1) ECSP10010400A (es)
IL (1) IL206640A0 (es)
MA (1) MA32073B1 (es)
MX (1) MX2010008940A (es)
NZ (1) NZ586666A (es)
PA (1) PA8816001A1 (es)
PE (1) PE20091471A1 (es)
TN (1) TN2010000302A1 (es)
TW (1) TW200940095A (es)
UA (1) UA102680C2 (es)
UY (1) UY31660A1 (es)
WO (1) WO2009101021A2 (es)
ZA (1) ZA201006517B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
EP2874824A1 (en) 2012-07-23 2015-05-27 Crayola LLC Dissolvable films and methods of using the same
KR102091852B1 (ko) * 2015-03-02 2020-03-23 코로나리콘셉츠 엘엘씨 Peg 대사산물 및 peg 분해 생성물 검정을 위한 화합물 및 방법

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
WO1993023011A1 (en) * 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
DE4426709A1 (de) * 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
JP2002512185A (ja) * 1998-04-17 2002-04-23 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 葉酸を含有する製薬学的組成物並びに関連する方法及び送達系
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
SK14632002A3 (sk) * 2000-04-12 2003-03-04 Schering Aktiengesellschaft Substituované estratriény a ich použitie ako selektívne účinných estrogénov
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
US20030004145A1 (en) * 2001-05-16 2003-01-02 Leonard Thomas W. Treatment of conditions relating to hormone deficiencies by administration of progestins
CA2419089A1 (en) * 2001-07-27 2003-03-05 Tatsuki Shinoda Composition comprises sustained-release fine particles for quick-disintegrating tablets in the buccal cavity and manufacturing method thereof
ES2274107T3 (es) * 2002-02-21 2007-05-16 Bayer Schering Pharma Ag Composiciones farmaceuticas comprendiendo uno o mas esterioides, uno o mas componentes de tetrahidrofolato vitamina b12.
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
US20070059346A1 (en) * 2003-07-01 2007-03-15 Todd Maibach Film comprising therapeutic agents
KR20060126688A (ko) * 2003-12-09 2006-12-08 다이닛본 스미토모 세이야꾸 가부시끼가이샤 약물-함유 입자 및 그 입자를 함유하는 고형 제제
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
US20060275364A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Flexible Solid Dosage Forms and Methods of Making and Using the Same
DE102005058569B4 (de) * 2005-12-08 2010-07-15 Lts Lohmann Therapie-Systeme Ag Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
EP1867321A3 (en) * 2006-06-07 2008-11-19 Familplan Consulting Ltd. A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
US20080058272A1 (en) * 2006-08-29 2008-03-06 Juergen Becker Nonamer Peptides for Cancer Treatment

Also Published As

Publication number Publication date
CN101945646A (zh) 2011-01-12
EA201001245A1 (ru) 2011-04-29
WO2009101021A2 (en) 2009-08-20
BRPI0908477A2 (pt) 2018-03-27
ZA201006517B (en) 2014-02-26
CL2009000326A1 (es) 2010-07-19
CR11632A (es) 2010-10-05
TW200940095A (en) 2009-10-01
TN2010000302A1 (en) 2011-11-11
AR070375A1 (es) 2010-03-31
PE20091471A1 (es) 2009-10-25
MA32073B1 (fr) 2011-02-01
AU2009214193A1 (en) 2009-08-20
NZ586666A (en) 2012-04-27
UA102680C2 (ru) 2013-08-12
DOP2010000252A (es) 2010-08-31
CO6290633A2 (es) 2011-06-20
IL206640A0 (en) 2010-12-30
KR20100125309A (ko) 2010-11-30
CA2714340A1 (en) 2009-08-20
ECSP10010400A (es) 2010-09-30
WO2009101021A3 (en) 2009-12-30
UY31660A1 (es) 2009-09-30
EP2249803A2 (en) 2010-11-17
JP2011511823A (ja) 2011-04-14
PA8816001A1 (es) 2009-09-17
US20110097405A1 (en) 2011-04-28

Similar Documents

Publication Publication Date Title
WO2013188819A3 (en) Mucoadhesive devices for delivery of active agents
MX367868B (es) Composiciones antimicrobianas.
MX2019001253A (es) Conjugados de proteina-agente activo y metodo para su preparacion.
EP3895700A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
MX2022001251A (es) Composiciones y metodos para reducir eventos adversos cardiovasculares graves.
GEP20146057B (en) Alcoholic compositions having lowered risk of acetaldehydemia
GEP20156241B (en) Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
WO2013055689A8 (en) R(+)-n-methyl-propargyl-aminoindan
MX2010008940A (es) Sistemas de administracion de drogas que contienen estradiol.
EP2649318A4 (en) Discharge vacuum relief valve for safety vacuum release system
MX353623B (es) Sistema de suministro de farmaco.
MX360235B (es) Composicion para evitar o tratar osteoporosis y metodo de manufactura para el mismo.
NZ595484A (en) Method of treating hepatocellular carcinoma
EP2083806A4 (en) USE OF AN ANTI-CANCER COMPOUND
WO2012064396A3 (en) Novel ezrin inhibitors and methods of making and using
MX2015007794A (es) Suministro transmucosal de acetato de glatiramer mediante parches orales.
WO2012134172A3 (ko) 오미자 에틸아세테이트 분획물 또는 이로부터 분리한 우웨이지수 ｃ를 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
WO2012155226A8 (pt) Processo para a produção de derivados de pyrostegia venusta, derivados de pyrostegia venusta, composições farmacêuticas e seus usos
WO2012048285A8 (en) Delivery of bisphosphonates by microinjection systems
IN2012DE00826A (es)
MX337145B (es) Composiciones farmaceuticas.
CU20100164A7 (es) Sistemas de administración de drogas que contienen estradiol
WO2010104588A3 (en) Compositions and methods for characterizing and treating neoplasia
WO2008127640A3 (en) Substituted benzimidazoles
TH105098A (th) ระบบนำส่งยาที่ประกอบด้วยเอสทราไดออล